
-
VBI Vaccines NASDAQ:VBIV VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
Location: | Website: www.vbivaccines.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
1.04%
Insider Ownership
6.77%
Institutional Own.
13.04%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PreHevbrio (Sci-B-Vac®) Details Hepatitis B, Hepatitis B vaccine, Pain | Approved Quarterly sales | |
VBI-1901 (eVLP) Details Glioblastoma, Cancer | Phase 2b Data readout | |
VBI-2601 (BRII-179) combo w/ PEG-IFNα Details Chronic hepatitis B, Hepatitis B | Phase 2 Update | |
VBI-1901 (eVLP) Details Glioblastoma, Cancer | Phase 2 Initiation | |
VBI-2902 Details COVID-19 | Phase 1/2 Data readout | |
VBI-2905 Details COVID-19 | Phase 1/2 Update | |
VBI-2901 Details COVID-19 | Phase 1 Data readout | |
VBI-1501 Details Cytomegalovirus | Phase 1 Update |